Patients with metastatic neuroendocrine tumor with plan to receive four cycles of lutetium-177 were enrolled. Clonal hematopoiesis was evaluated before peptide receptor radionuclide therapy using a panel of 220 genes with a targeted depth of greater or equal to 1,000×.
[JCO Precision Oncology]
